These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9442450)

  • 1. Vomiting induction by ipecac syrup in dogs and ferrets.
    Yamashita M; Yamashita M; Tanaka J; Chagi K; Takeda S; Kurihara T; Takeda Y; Fujii Y
    J Toxicol Sci; 1997 Dec; 22(5):409-12. PubMed ID: 9442450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological aspects of ipecac syrup (TJN-119)-induced emesis in ferrets.
    Endo T; Nemoto M; Ogawa T; Tamakai H; Hamaue N; Hirafuji M; Takeda Y; Hasegawa M; Fugii Y; Minami M
    Res Commun Mol Pathol Pharmacol; 2000; 108(3-4):187-200. PubMed ID: 11913711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of emetic and United State pharmacopoeia ipecac syrup in prevention of drug absorption.
    Teshima D; Suzuki A; Otsubo K; Higuchi S; Aoyama T; Shimozono Y; Saita M; Noda K
    Chem Pharm Bull (Tokyo); 1990 Aug; 38(8):2242-5. PubMed ID: 1980639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broad spectrum antiemetic effects of CP-122,721, a tachykinin NK1 receptor antagonist, in ferrets.
    Gonsalves S; Watson J; Ashton C
    Eur J Pharmacol; 1996 Jun; 305(1-3):181-5. PubMed ID: 8813551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor.
    Watson JW; Gonsalves SF; Fossa AA; McLean S; Seeger T; Obach S; Andrews PL
    Br J Pharmacol; 1995 May; 115(1):84-94. PubMed ID: 7544198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040.
    Gardner CJ; Twissell DJ; Dale TJ; Gale JD; Jordan CC; Kilpatrick GJ; Bountra C; Ward P
    Br J Pharmacol; 1995 Dec; 116(8):3158-63. PubMed ID: 8719790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies for the emetic mechanisms of ipecac syrup (TJN-119) and its active components in ferrets: involvement of 5-hydroxytryptamine receptors.
    Hasegawa M; Sasaki T; Sadakane K; Tabuchi M; Takeda Y; Kimura M; Fujii Y
    Jpn J Pharmacol; 2002 Jun; 89(2):113-9. PubMed ID: 12120752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of 15-mL versus 30-mL doses of syrup of ipecac in children.
    Krenzelok EP; Dean BS
    Clin Pharm; 1987 Sep; 6(9):715-7. PubMed ID: 2890461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preserving the emetic effect of syrup of ipecac with concurrent activated charcoal administration: a preliminary study.
    Krenzelok EP; Freedman GE; Pasternak S
    J Toxicol Clin Toxicol; 1986; 24(2):159-66. PubMed ID: 2872336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of zatosetron on ipecac-induced emesis in dogs and healthy men.
    Schwartz SM; Goldberg MJ; Gidda JS; Cerimele BJ
    J Clin Pharmacol; 1994 Mar; 34(3):250-4. PubMed ID: 7517409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of maropitant and selected drugs in preventing emesis induced by centrally or peripherally acting emetogens in dogs.
    Sedlacek HS; Ramsey DS; Boucher JF; Eagleson JS; Conder GA; Clemence RG
    J Vet Pharmacol Ther; 2008 Dec; 31(6):533-7. PubMed ID: 19000276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical trial using syrup of ipecac and activated charcoal concurrently.
    Freedman GE; Pasternak S; Krenzelok EP
    Ann Emerg Med; 1987 Feb; 16(2):164-6. PubMed ID: 2879488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of three preclinical models for nausea and vomiting assessment.
    Goineau S; Castagné V
    J Pharmacol Toxicol Methods; 2016; 82():45-53. PubMed ID: 27477617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expired ipecac syrup efficacy.
    Grbcich PA; Lacouture PG; Kresel JJ; Russell MT; Lovejoy FH
    Pediatrics; 1986 Dec; 78(6):1085-9. PubMed ID: 2878409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting the emetic liability of novel chemical entities: a comparative study.
    du Sert NP; Holmes AM; Wallis R; Andrews PL
    Br J Pharmacol; 2012 Mar; 165(6):1848-1867. PubMed ID: 21913900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guideline on the use of ipecac syrup in the out-of-hospital management of ingested poisons.
    Manoguerra AS; Cobaugh DJ;
    Clin Toxicol (Phila); 2005; 43(1):1-10. PubMed ID: 15732439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluphenazine, ICS 205-930 and dl-fenfluramine differentially antagonise drug-induced emesis in the ferret.
    Costall B; Domeney AM; Naylor RJ; Owera-Atepo JB; Rudd JA; Tattersall FD
    Neuropharmacology; 1990 May; 29(5):453-62. PubMed ID: 1972549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiles of emetic action of cisplatin in the ferret: a potential model of acute and delayed emesis.
    Rudd JA; Jordan CC; Naylor RJ
    Eur J Pharmacol; 1994 Sep; 262(1-2):R1-2. PubMed ID: 7813558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphine 6-glucuronide: a metabolite of morphine with greater emetic potency than morphine in the ferret.
    Thompson PI; Bingham S; Andrews PL; Patel N; Joel SP; Slevin ML
    Br J Pharmacol; 1992 May; 106(1):3-8. PubMed ID: 1324067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret.
    Rudd JA; Naylor RJ
    Br J Pharmacol; 1996 May; 118(2):209-14. PubMed ID: 8735616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.